Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB074 (Vixotrigine) in Trigeminal Neuralgia
NCT03070132Phase 3Withdrawn
- Sponsor
- Biogen
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in trigeminal neuralgia (TN) comparing BIIB074 with Placebo (2 arms). Primary endpoints: Percentage of Participants Classified as Responders at 12 weeks and Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Long Term Extension (LTE) Period at 52 weeks. Planned start Apr 2023; status: withdrawn.
02
Drugs
vixotrigine
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT03070132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070132.